Abstract：
Dermatologic surgeons are encountering more patients on antithrombotic agents. There are no established consensus guidelines for managing antithrombotic agents in the perioperative period. We provide an updated overview of antithrombotic agents in dermatologic surgery and management of such agents in the perioperative period with additional unique perspectives from cardiology and pharmacy. A literature search of PubMed and Google Scholar was performed to review the English-language medical literature. The landscape of antithrombotic therapy is changing with a notable rise in the use of direct oral anticoagulants (DOACs.) While no consensus guidelines exist, most studies recommend continuing antithrombotic therapy in the perioperative period with appropriate lab monitoring, when applicable. However, recent data suggest it is safe to hold DOACs in the perioperative period. As antithrombotic therapy evolves, the dermatologic surgeon needs to remain current with the most recent available data. Where data are limited, a multidisciplinary approach to managing these agents in the perioperative period is essential. J Drugs Dermatol. 2023;22(5): doi:10.36849/JDD.7456.
摘要：
皮肤科医生遇到了更多使用抗血栓药物的患者。对于围手术期抗血栓药物的管理，尚无既定的共识指南。我们提供了皮肤科手术中抗血栓药物的最新概述以及围手术期此类药物的管理，并从心脏病学和药学方面提供了其他独特的观点。对PubMed和GoogleScholar进行了文献检索，以审查英语医学文献。随着直接口服抗凝药（DOACs。)虽然没有共识准则，大多数研究建议在围手术期继续抗血栓治疗，并进行适当的实验室监测，适用时。然而,最近的数据表明在围手术期保留DOAC是安全的。随着抗血栓治疗的发展，皮肤科外科医生需要保持最新的现有数据。如果数据有限，在围手术期采用多学科方法管理这些药物至关重要.J药物Dermatol.2023年；22（5）：doi：10.36849/JD.7456。
